Loading...
Loading...
- Quest Diagnostics Incorporated DGX posted better-than-expected second-quarter results, as vaccinations and the lifting of lockdowns resulted in recovery in its core non-coronavirus testing businesses.
- Q2 adjusted EPS surged almost 125% Y/Y at $3.18, beating the consensus estimate of $2.86.
- Sales came in at $2.6 billion, increased 40% Y/Y, and higher than the Wall Street estimate of $2.4 billion.
- Q2 revenue from the diagnostic information services business, which provides tests for cancer, cardiovascular diseases, infectious diseases, and neurology, was up 40% to $2.6 billion.
- Quest's rival Abbott Laboratories ABT recorded improvements in its non-COVID-19 businesses as vaccinated Americans become more comfortable visiting doctors.
- "This was the first quarter since 2019 that organic base testing revenues grew in the quarter," Chief Executive Officer Steve Rusckowski said in a statement.
- Outlook: Banking on the improvements, Quest forecast full-year revenue of $9.54 billion - $9.79 billion, higher than the analyst consensus of $9.45 billion.
- It also estimated annual adjusted EPS of $10.65 and $11.35, the mid-pint being lower than the Wall Street estimate of $11.13.
- Price Action: DGX shares are down 0.57% at $135 during the premarket session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in